HDAC9 and cancer: HDACi, trichostatin A (TSA) [12,13] or vorinostat (SAHA)[14–16] inhibit class I and II HDAC enzymes, resulting in growth arrest, apoptosis, differentiation, and anti-angiogenesis of cancer cells, when used independently or in combination with other anti-cancer agents.